1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252‑271, 2014.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394‑424, 2018.
3. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, et al; Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25: 1‑42, 2020.
4. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11: 38‑47, 2010.
5. Majeed AW: Surgery for colorectal liver metastases with hepatic lymph node involvement: A systematic review. Br J Surg 87: 1737, 2000.
6. Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 9: 853‑878, 2000.
7. Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 82: 1075‑1090, x‑xi, 2002.
8. Fidler IJ and Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893‑895, 1977.
9. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY and Singh RK: Transforming growth factor‑beta signaling at the tumor‑bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 100: 71‑81, 2009.
10. Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, Tanabe T, Naruoka A, Kamada F, Serizawa M, et al: Japanese version of The Cancer Genome Atlas, JCGA, estab‑ lished using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci 111: 687‑699, 2020.
11. Japanese ethical guidelines for human genome/gene analysis research. https://www.mhlw.go.jp/general/seido/kousei/i‑ kenkyu/genome/0504sisin.html. Accessed: March 25, 2021.
12. Ion Reporter Software User Guide: Tumor‑Normal pair workflow. https://tools.thermofisher.com/content/sfs/manuals/ IonReporter_v50_Help.pdf. Accessed: March 25, 2021.
13. Torrent Suite v4.4.3 User and Admin Guide. https://assets. thermofisher.com/TFS‑Assets/LSG/manuals/MAN0019144_ TorrentSuite_5_14_UG.pdf. Accessed: March 25, 2021.
14. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G and Mesirov JP: Integrative genomics viewer. Nat Biotechnol 29: 24‑26, 2011.
15. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, et al: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355‑358, 2004.
16. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM and Maglott DR: ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42: D980‑D985, 2014.
17. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of genetic variation. Nucleic Acids Res : 308‑311, 2001.
18. UniProt Consortium: UniProt: A hub for protein information. Nucleic Acids Res 43: D204‑D212, 2015.
19. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z and Woolsey J: DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34: D668‑D672, 2006.
20. Nagashima T, Shimoda Y, Tanabe T, Naruoka A, Saito J, Serizawa M, Ohshima K, Urakami K, Ohnami S, Ohnami S, et al: Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples. Biomed Res 37: 359‑366, 2016.
21. Shimoda Y, Nagashima T, Urakami K, Tanabe T, Saito J, Naruoka A, Serizawa M, Mochizuki T, Ohshima K, Ohnami S, et al: Integrated next‑generation sequencing analysis of whole exome and 409 cancer‑related genes. Biomed Res 37: 367‑379, 2016.
22. Urakami K, Shimoda Y, Ohshima K, Nagashima T, Serizawa M, Tanabe T, Saito J, Usui T, Watanabe Y, Naruoka A, et al: Next generation sequencing approach for detecting 491 fusion genes from human cancer. Biomed Res 37: 51‑62, 2016.
23. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al: The consensus molecular subtypes of colorectal cancer. Nat Med 21: 1350‑1356, 2015.
24. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, et al: A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19: 619‑625, 2013.
25. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD‑1 blockade in tumors with mismatch‑repair deficiency. N Engl J Med 372: 2509‑2520, 2015.
26. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science 357: 409‑413, 2017.
27. Polanska UM and Orimo A: Carcinoma‑associated fibroblasts: Non‑neoplastic tumour‑promoting mesenchymal cells. J Cell Physiol 228: 1651‑1657, 2013.
28. Ishii G, Ochiai A and Neri S: Phenotypic and functional heterogeneity of cancer‑associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99: 186‑196, 2016.
29. Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, Iekushi K, Koibuchi N, Sanada F, Oshita Y and Morishita R: Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti‑periostin antibody in a murine model. Int J Mol Med 28: 181‑186, 2011.
30. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA and Friess H: Periostin creates a tumor‑supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132: 1447‑1464, 2007.
31. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M and Takata T: Periostin promotes invasion and anchorage‑independent growth in the metastatic process of head and neck cancer. Cancer Res 66: 6928‑6935, 2006.
32. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, et al: Expression of periostin in human breast cancer. J Clin Pathol 61: 494‑498, 2008.
33. Moniuszko T, Wincewicz A, Koda M, Domysławska I and Sulkowski S: Role of periostin in esophageal, gastric and colon cancer. Oncol Lett 12: 783‑787, 2016.
34. Sodek J, Ganss B and McKee MD: Osteopontin. Crit Rev Oral Biol Med 11: 279‑303, 2000.
35. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K and Fukuchi Y: Differential osteo‑ pontin expression in lung cancer. Cancer Lett 171: 215‑222, 2001.
36. Song G, Cai QF, Mao YB, Ming YL, Bao SD and Ouyang GL: Osteopontin promotes ovarian cancer progression and cell survival and increases HIF‑1alpha expression through the PI3‑K/Akt pathway. Cancer Sci 99: 1901‑1907, 2008.
37. Kim JY, Bae BN, Kim KS, Shin E and Park K: Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat 41: 29‑35, 2009.
38. Likui W, Hong W and Shuwen Z: Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 14: 74‑81, 2010.
39. Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al‑Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, et al: Assessment of osteopontin in early breast cancer: Correlative study in a randomised clinical trial. Breast Cancer Res 16: R8, 2014.
40. Zhao M, Liang F, Zhang B, Yan W and Zhang J: The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: A systematic meta‑analysis. Sci Rep 5: 12713, 2015.
41. Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T, et al: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 79: 354‑359, 1999.
42. de Fraipont F, Nicholson AC, Feige JJ and Van Meir EG: Thrombospondins and tumor angiogenesis. Trends Mol Med 7: 401‑407, 2001.
43. Kim H, Watkinson J, Varadan V and Anastassiou D: Multi‑cancer computational analysis reveals invasion‑associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics 3: 51, 2010.
44. Tian Q, Liu Y, Zhang Y, Song Z, Yang J, Zhang J, Guo T, Gao W, Dai F and He C: THBS2 is a biomarker for AJCC stages and a strong prognostic indicator in colorectal cancer. J BUON 23: 1331‑1336, 2018.
45. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM and Wang XF: Bone‑related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278: 15951‑15957, 2003.
46. Kuan CT, Wakiya K, Dowell JM, Herndon JE II, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ and Bigner DD: Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12: 1970‑1982, 2006.
47. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M and Siegel PM: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5: 1001‑1014, 2007.
48. Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M and Siegel PM: ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One 5: e12093, 2010.
49. Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St‑Pierre Y, Simantov R, Hallett M, Park M, et al: Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16: 2147‑2156, 2010.
50. Taya M and Hammes SR: Glycoprotein non‑metastatic melanoma protein B (GPNMB) and cancer: A novel potential therapeutic target. Steroids 133: 102‑107, 2018.
51. Zhou LT, Liu FY, Li Y, Peng YM, Liu YH and Li J: Gpnmb/ osteoactivin, an attractive target in cancer immunotherapy. Neoplasma 59: 1‑5, 2012.
52. Selim AA: Osteoactivin bioinformatic analysis: Prediction of novel functions, structural features, and modes of action. Med Sci Monit 15: MT19‑MT33, 2009.
53. Singh M, Del Carpio‑Cano F, Belcher JY, Crawford K, Frara N, Owen TA, Popoff SN and Safadi FF: Functional roles of osteo‑ activin in normal and disease processes. Crit Rev Eukaryot Gene Expr 20: 341‑357, 2010.
54. Mertsch S, Schurgers LJ, Weber K, Paulus W and Senner V: Matrix gla protein (MGP): An overexpressed and migration‑promoting mesenchymal component in glioblastoma. BMC Cancer 9: 302, 2009.
55. Kuzontkoski PM, Mulligan‑Kehoe MJ, Harris BT and Israel MA: Inhibitor of DNA binding‑4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene 29: 3793‑3802, 2010.
56. Gheorghe SR and Crăciun AM: Matrix Gla protein in tumoral pathology. Clujul Med 89: 319‑321, 2016.
57. Caiado H, Conceição N, Tiago D, Marreiros A, Vicente S, Enriquez JL, Vaz AM, Antunes A, Guerreiro H, Caldeira P, et al: Evaluation of MGP gene expression in colorectal cancer. Gene 723: 144120, 2020.
58. Hope NR and Murray GI: The expression profile of RNA‑binding proteins in primary and metastatic colorectal cancer: Relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol 42: 393‑402, 2011.
59. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al: Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30: 2956‑2962, 2012.
60. Schrijver WAME, Selenica P, Lee JY, Ng CKY, Burke KA, Piscuoglio S, Berman SH, Reis‑Filho JS, Weigelt B, van Diest PJ, etal: Mutation profiling of key cancer genes in primary breast cancers and their distant metastases. Cancer Res 78: 3112‑3121, 2018.
61. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole‑genome sequencing. Nature 481: 506‑510, 2012.
62. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al: Mutational analysis reveals the origin and therapy‑driven evolution of recurrent glioma. Science 343: 189‑193, 2014.
63. Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, et al: Comparative sequence analysis of patient‑matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer 19: 255, 2019.
64. Gagnière J, Dupré A, Gholami SS, Pezet D, Boerner T, Gönen M, Kingham TP, Allen PJ, Balachandran VP, De Matteo RP, et al: Is hepatectomy justified for BRAF mutant colorectal liver metastases?: A multi‑institutional analysis of 1497 patients. Ann Surg 271: 147‑154, 2020.
65. Wu Y, Denhardt DT and Rittling SR: Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83: 156‑163, 2000.
66. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT and Noda M: Osteopontin defi‑ ciency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16: 652‑659, 2001.
67. Wu XL, Lin KJ, Bai AP, Wang WX, Meng XK, Su XL, Hou MX, Dong PD, Zhang JJ, Wang ZY, et al: Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells. World J Gastroenterol 20: 10440‑10448, 2014.
68. Wei R, Wong JPC and Kwok HF: Osteopontin ‑ a promising biomarker for cancer therapy. J Cancer 8: 2173‑2183, 2017.
69. Rose AAN, Biondini M, Curiel R and Siegel PM: Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. Pharmacol Ther 179: 127‑141, 2017.
論文の公開元へ
